Waypoint Bio
AI · Biotech
Waypoint Bio secures $20M Series A for AI-designed cell therapies
June 1, 2026$20M · Series A
Waypoint Bio closed a $20 million Series A led by Amplify Partners to advance its WAY-103 program toward a late-2026 trial.
Lead Investors
Amplify Partners
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.